Home » Stocks » ALLO

Allogene Therapeutics, Inc. (ALLO)

Stock Price: $30.76 USD -0.58 (-1.85%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $30.60 -0.16 (-0.52%) Jan 22, 4:23 PM
Market Cap 4.32B
Revenue (ttm) n/a
Net Income (ttm) -242.68M
Shares Out 127.14M
EPS (ttm) -2.13
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $30.76
Previous Close $31.34
Change ($) -0.58
Change (%) -1.85%
Day's Open 30.67
Day's Range 30.43 - 31.29
Day's Volume 458,511
52-Week Range 18.22 - 54.04

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 1 month ago

The FDA permits Allogene (ALLO) to initiate an early-stage study on its AlloCAR T therapy candidate, ALLO-715, in combination with SpringWorks' nirogacestat in multiple myeloma patients.

GlobeNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...

Seeking Alpha - 1 month ago

Overland Pharmaceuticals will form a $117 million China JV with Allogene Therapeutics to bring allogenic CAR-T drugs to China. Harbour BioMed has out-licensed its fully human SARS-CoV-2 neutra...

Other stocks mentioned: ABBV, ADCT, BNTX, LEGN, YMAB
GlobeNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif. and BOSTON and SHANGHAI, China, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the ...

GlobeNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...

GlobeNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif., Dec. 06, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...

GlobeNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif., Dec. 05, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...

Zacks Investment Research - 1 month ago

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?

GlobeNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...

Seeking Alpha - 1 month ago

Allogeneic cell therapies have a significant cost, convenience and efficiency advantage over autologous. Data from three of the leaders: Allogene, Atara and CRISPR are expected in the next 12-...

Other stocks mentioned: ATRA, BMY, CLLS, CRSP, GILD, NVS, PFE
GlobeNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...

Seeking Alpha - 2 months ago

Allogene Therapeutics' (ALLO) CEO David Chang on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Allogene (ALLO) reports no revenues for the third quarter of 2020.

GlobeNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...

GlobeNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...

GlobeNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...

GlobeNewsWire - 3 months ago

SOUTH SAN FRANCISCO, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...

Zacks Investment Research - 4 months ago

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?

GlobeNewsWire - 4 months ago

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CA...

Kiplinger - 5 months ago

It's not uncommon for stocks that have significantly outperformed for several months to take a breather.

Other stocks mentioned: DKNG, MYOK, PLUG, UTHR, XLRN, YY
Zacks Investment Research - 5 months ago

Allogene (ALLO) reports no revenues for the second quarter of 2020.

Seeking Alpha - 5 months ago

Allogene Therapeutics' (ALLO) CEO David Chang on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR...

The Motley Fool - 5 months ago

Their groundbreaking research on CAR T-cell therapies could revolutionize how certain cancers are treated in the future.

Other stocks mentioned: CLLS, GILD, NVS, TCRR
GlobeNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR...

GlobeNewsWire - 6 months ago

SOUTH SAN FRANCISCO, Calif., July 07, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR...

Benzinga - 6 months ago

Shares of Allogene Therapeutics Inc (NASDAQ:ALLO) moved lower by 2% from the previous closing price.

GlobeNewsWire - 6 months ago

SOUTH SAN FRANCISCO, Calif., July 01, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR...

Zacks Investment Research - 6 months ago

Is (ALLO) Outperforming Other Medical Stocks This Year?

GlobeNewsWire - 7 months ago

SOUTH SAN FRANCISCO, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR...

GlobeNewsWire - 7 months ago

SOUTH SAN FRANCISCO, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR...

Zacks Investment Research - 7 months ago

Is (ALLO) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 7 months ago

Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?

GlobeNewsWire - 7 months ago

SOUTH SAN FRANCISCO, Calif., June 01, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), today announced the pricing of an underwritten public offering of 11,702,128 shares...

Benzinga - 7 months ago

Allogene Therapeutics (NASDAQ: ALLO) shares were trading lower on Monday. The company announced it would commence a $450 million offering of its common stock.

GlobeNewsWire - 7 months ago

SOUTH SAN FRANCISCO, Calif., June 01, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), today announced the commencement of an underwritten public offering of $450.0 milli...

Zacks Investment Research - 7 months ago

Allogene Therapeutics, Inc. (ALLO) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Zacks Investment Research - 8 months ago

Is (ALLO) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 8 months ago

Investors need to pay close attention to Allogene (ALLO) stock based on the movements in the options market lately.

Zacks Investment Research - 8 months ago

Allogene Therapeutics (ALLO) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Benzinga - 8 months ago

The American Society of Clinical Oncology annual conference brings together oncology professionals, patient advocates, industry representatives, and major media outlets from across the globe.

Other stocks mentioned: AMGN, ARVN, CTMX, MGNX
The Motley Fool - 8 months ago

The development-stage biopharma reported encouraging, albeit early, data from an important pipeline program.

Zacks Investment Research - 8 months ago

As of late, it has definitely been a great time to be an investor Allogene Therapeutics

Seeking Alpha - 8 months ago

Autolus: A Highly Undervalued CAR-T Company

Zacks Investment Research - 8 months ago

Allogene (ALLO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Seeking Alpha - 8 months ago

Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Allogene (ALLO) reports no revenues for the first quarter of 2020.

Zacks Investment Research - 8 months ago

Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.

Other stocks mentioned: ACAD, ALNY, ALXN, HZNP
Zacks Investment Research - 8 months ago

Allogene Therapeutics (ALLO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season

GlobeNewsWire - 8 months ago

SOUTH SAN FRANCISCO, Calif. and PARIS, April 29, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of all...

About ALLO

Allogene Therapeutics, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and A... [Read more...]

Industry
Biotechnology
IPO Date
Oct 11, 2018
Stock Exchange
NASDAQ
Ticker Symbol
ALLO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 17 analysts, the average rating for ALLO stock is "Buy." The 12-month stock price forecast is 48.92, which is an increase of 59.04% from the latest price.

Price Target
$48.92
(59.04% upside)
Analyst Consensus: Buy